STOCK TITAN
  1. Home
  2. News
  3. BCRX

Biocryst Pharmaceuticals Inc. - BCRX STOCK NEWS

Welcome to our dedicated news page for Biocryst Pharmaceuticals (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocryst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocryst Pharmaceuticals's position in the market.

News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst's board of directors granted 11 newly-hired employees stock options to purchase 80,700 shares and restricted stock units (RSUs) covering 38,600 shares of BioCryst common stock. The options and RSUs were granted on October 31, 2023, with an exercise price of $5.49 per share, equal to the closing price on the grant date. They vest in four equal annual installments starting on the one-year anniversary of the grant date, subject to the new employee's continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
none
-
News
BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
Rhea-AI Summary
BioCryst Pharmaceuticals announces updates from its drug discovery process and additional therapies from its pipeline. They highlight BCX17725 for Netherton syndrome, a fusion protein for complex complement-mediated diseases, an oral C5 program for generalized myasthenia gravis, and avoralstat for diabetic macular edema. The company plans to begin clinical trials for these therapies in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
clinical trial
-
News
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®
Rhea-AI Summary
BioCryst Pharmaceuticals and Clearside Biomedical have entered into a license agreement for the development of avoralstat, a plasma kallikrein inhibitor, to treat patients with diabetic macular edema (DME). Avoralstat will be delivered directly to the back of the eye through Clearside's SCS Microinjector. The collaboration aims to advance avoralstat into a proof-of-concept trial as a potential best-in-class medicine for DME patients. Clearside will receive a $5 million upfront license fee and is eligible for up to $77.5 million in milestone payments. DME is the leading cause of vision loss in individuals with diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
partnership
News
BioCryst Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. reported Q3 2023 net revenue of $85.7 million (+29.8% YoY) for ORLADEYO, expecting to achieve at least $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue. Net cash utilization was $16.5 million in Q3 2023 (-43.9% YoY). The company will host an R&D Day on November 3rd to introduce additional therapies from its pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
earnings
-
News
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
Rhea-AI Summary
BioCryst Pharmaceuticals will present two abstracts on ORLADEYO at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology. The abstracts discuss the reduction of attack rates in patients with hereditary angioedema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
-
News
BioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
Rhea-AI Summary
BioCryst Pharmaceuticals has enrolled the first patient in a proof-of-concept clinical trial for BCX10013, an oral Factor D inhibitor for complement-mediated diseases. The trial aims to evaluate the preliminary efficacy and safety profile of once-daily dosing with BCX10013. If successful, the company plans to advance into a pivotal program for renal complement-mediated diseases. BioCryst is committed to developing best-in-class medicines for patients with unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
News
BioCryst to Host R&D Day on November 3
Rhea-AI Summary
BioCryst Pharmaceuticals to host R&D Day to discuss drug discovery process and introduce new therapies
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences
-
News
BioCryst to Report Third Quarter 2023 Financial Results on November 2
Rhea-AI Summary
BioCryst Pharmaceuticals to report Q2 2023 financial results on November 2nd
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
conferences earnings
-
News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BioCryst Pharmaceuticals grants stock options and restricted stock units to newly-hired employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.65%
Tags
none
News
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BioCryst Pharmaceuticals grants stock options and RSUs to newly-hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
Stock BCRX logo
Biocryst Pharmaceuticals Inc.

Nasdaq:BCRX

BCRX Rankings

#2464 Ranked by Market Cap
#4914 Ranked by Stock Gains
N/A Ranked by Dividends

BCRX Stock Data

950.35M
190.88M
1.21%
88.11%
15.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.